DelveInsight’s ‘Soft Tisue Sarcoma (STS) with lung metastases—Epidemiology Forecast–2030’ report delivers an in-depth understanding of the STS with lung metastases, historical and forecasted epidemiology as well as the STS with lung metastases trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
Study Period: 2017–2030
Soft tissue sarcoma is a broad term for cancers that start in soft tissues (muscle, tendons, fat, lymph and blood vessels, and nerves). These cancers can develop anywhere in the body but are found mostly in the arms, legs, chest, and abdomen. The lung is the most frequent site of metastasis from soft-tissue sarcomas. From several studies, it has been estimated that around 50–60% of the STS cases develop lung metastases.
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total incident cases of Soft tissue sarcoma, Total incident cases of STS with lung metastases, Gender-specific incident cases of STS with lung metastases, and Subtype-specific incident cases of STS with lung metastases scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017 to 2030.
The STS with lung metastases report will allow the user to -
1 Key Insights
2 Executive Summary of STS with lung metastases
3 Disease Background and Overview: STS with lung metastases
3.1 Introduction
3.2 General symptoms of lung metastases
3.3 Prognostic factors
3.3.1 Histology
3.3.2 Disease-free interval (DFI)
3.3.3 Completeness of resection
3.3.4 Response to chemotherapy
3.4 Staging System
3.5 Diagnosis of Soft-Tissue Sarcomas with Lung Metastases
4 Epidemiology and Patient Population
4.1 Key Findings
4.2 Epidemiology Methodology
4.3 Total Incident Cases of Soft Tissue Sarcoma (STS) in the 7MM
4.4 Total Incident Cases of STS with lung metastases in the 7MM
5 United States Epidemiology
5.1 Assumptions and Rationale
5.2 Total Incident cases of Soft tissue sarcoma (STS) in the United States
5.3 Total incident cases of STS with lung metastases in the United States
5.4 Gender-specific incident cases of STS with lung metastases in the United States
5.5 Subtype-specific incident cases of STS with lung metastases in the United States
6 EU5 Epidemiology
6.1 Assumptions and Rationale
6.2 Germany Epidemiology
6.2.1 Total incident cases of Soft tissue sarcoma (STS) in Germany
6.2.2 Total incident cases of STS with lung metastases in Germany
6.2.3 Gender-specific incident cases of STS with lung metastases in Germany
6.2.4 Subtype-specific incident cases of STS with lung metastases in Germany
6.3 France Epidemiology
6.3.1 Total incident cases of Soft tissue sarcoma (STS) in France
6.3.2 Total incident cases of STS with lung metastases in France
6.3.3 Gender-specific incident cases of STS with lung metastases in France
6.3.4 Subtype-specific incident cases of STS with lung metastases (%) in France
6.4 Italy Epidemiology
6.4.1 Total incident cases of Soft tissue sarcoma (STS) in Italy
6.4.2 Total incident cases of STS with lung metastases in Italy
6.4.3 Gender-specific incident cases of STS with lung metastases in Italy
6.4.4 Subtype-specific incident cases of STS with lung metastases in Italy
6.5 Spain Epidemiology
6.5.1 Total incident cases of Soft tissue sarcoma (STS) in Spain
6.5.2 Total incident cases of STS with lung metastases in Spain
6.5.3 Gender-specific incident cases of STS with lung metastases in Spain
6.5.4 Subtype-specific incident cases of STS with lung metastases (%) in Spain
6.6 United Kingdom Epidemiology
6.6.1 Total incident cases of Soft tissue sarcoma (STS) in the United Kingdom
6.6.2 Total incident cases of STS with lung metastases in the UK
6.6.3 Gender-specific incident cases of STS with lung metastases in the UK
6.6.4 Subtype-specific incident cases of STS with lung metastases in the UK
7 Japan Epidemiology
7.1 Assumptions and Rationale
7.1.1 Total incident cases of Soft tissue sarcoma (STS) in Japan
7.1.2 Total incident cases of STS with lung metastases in Japan
7.1.3 Gender-specific incident cases of STS with lung metastases in Japan
7.1.4 Subtype-specific incident cases of STS with lung metastases (%) in Japan
8 Appendix
8.1 Bibliography
8.2 Report Methodology
9 DelveInsight Capabilities
10 Disclaimer
11 About DelveInsight
List of Table
Table 1: Summary of STS with lung metastases, Epidemiology and Key Events (2017–2030)
Table 2: Total Incident Cases of Soft Tissue Sarcoma (STS) in the 7MM (2017–2030)
Table 3: Total Incident Cases of STS with lung metastases in the 7MM (2017–2030)
Table 4: Total Incident cases of STS (Soft tissue sarcoma) in the United States (2017–2030)
Table 5: Total incident cases of STS with lung metastases in the United States (2017–2030)
Table 6: Gender-specific incident cases of STS with lung metastases in the US (2017–2030)
Table 7: Subtype-specific incident cases of STS with lung metastases in the US (2017–2030)
Table 8: Total incident cases of Soft tissue sarcoma (STS) in Germany (2017–2030)
Table 9: Total incident cases of STS with lung metastases in Germany (2017–2030)
Table 10: Gender-specific incident cases of STS with lung metastases in Germany (2017–2030)
Table 11: Subtype-specific incident cases of STS with lung metastases in Germany (2017–2030)
Table 12: Total incident cases of Soft tissue sarcoma (STS) in France (2017–2030)
Table 13: Total incident cases of STS with lung metastases in France (2017–2030)
Table 14: Gender-specific incident cases of STS with lung metastases in France (2017–2030)
Table 15: Subtype-specific incident cases of STS with lung metastases in France (2017–2030)
Table 16: Total incident cases of Soft tissue sarcoma (STS) in Italy (2017–2030)
Table 17: Total incident cases of STS with lung metastases in Italy (2017–2030)
Table 18: Gender-specific incident cases of STS with lung metastases in Italy (2017–2030)
Table 19: Subtype-specific incident cases of STS with lung metastases in Italy (2017–2030)
Table 20: Total incident cases of Soft tissue sarcoma (STS) in Spain (2017–2030)
Table 21: Total incident cases of STS with lung metastases in Spain (2017–2030)
Table 22: Gender-specific incident cases of STS with lung metastases in Spain (2017–2030)
Table 23: Subtype-specific incident cases of STS with lung metastases in Spain (2017–2030)
Table 24: Total incident cases of Soft tissue sarcoma (STS) in the UK (2017–2030)
Table 25: Total incident cases of STS with lung metastases in the UK (2017–2030)
Table 26: Gender-specific incident cases of STS with lung metastases in the UK (2017–2030)
Table 27: Subtype-specific incident cases of STS with lung metastases in the UK (2017–2030)
Table 28: Total incident cases of Soft tissue sarcoma (STS) in Japan (2017–2030)
Table 29: Total incident cases of STS with lung metastases in Japan (2017–2030)
Table 30: Gender-specific incident cases of STS with lung metastases in Japan (2017–2030)
Table 31: Subtype-specific incident cases of STS with lung metastases in Japan (2017–2030)
List of Figures
Figure 1: Diagnosis of Soft-Tissue Sarcoma with Lung Metastases
Figure 2: Imaging Tests for Soft-Tissue Sarcoma (STS)
Figure 3: Total Incident Cases of Soft Tissue Sarcoma (STS) in the 7MM (2017–2030)
Figure 4: Total Incident Cases of STS with lung metastases in the 7MM (2017–2030)
Figure 5: Total Incident cases of STS (Soft tissue sarcoma) in the United States (2017–2030)
Figure 6: Total incident cases of STS with lung metastases in the United States (2017–2030)
Figure 7: Gender-specific incident cases of STS with lung metastases in the US (2017–2030)
Figure 8: Subtype-specific incident cases of STS with lung metastases in the US (2017–2030)
Figure 9: Total incident cases of Soft tissue sarcoma (STS) in Germany (2017–2030)
Figure 10: Total incident cases of STS with lung metastases in Germany (2017–2030)
Figure 11: Gender-specific incident cases of STS with lung metastases in Germany (2017–2030)
Figure 12: Subtype-specific incident cases of STS with lung metastases in Germany (2017–2030)
Figure 13: Total incident cases of Soft tissue sarcoma (STS) in France (2017–2030)
Figure 14: Total incident cases of STS with lung metastases in France (2017–2030)
Figure 15: Gender-specific incident cases of STS with lung metastases in France (2017–2030)
Figure 16: Subtype-specific incident cases of STS with lung metastases in France (2017–2030)
Figure 17: Total incident cases of Soft tissue sarcoma (STS) in Italy (2017–2030)
Figure 18: Total incident cases of STS with lung metastases in Italy (2017–2030)
Figure 19: Gender-specific incident cases of STS with lung metastases in Italy (2017–2030)
Figure 20: Subtype-specific incident cases of STS with lung metastases in Italy (2017–2030)
Figure 21: Total incident cases of Soft tissue sarcoma (STS) in Spain (2017–2030)
Figure 22: Total incident cases of STS with lung metastases in Spain (2017–2030)
Figure 23: Gender-specific incident cases of STS with lung metastases in Spain (2017–2030)
Figure 24: Subtype-specific incident cases of STS with lung metastases in Spain (2017–2030)
Figure 25: Total incident cases of Soft tissue sarcoma (STS) in the UK (2017–2030)
Figure 26: Total incident cases of STS with lung metastases in the UK (2017–2030)
Figure 27: Gender-specific incident cases of STS with lung metastases in the UK (2017–2030)
Figure 28: Subtype-specific incident cases of STS with lung metastases in the UK (2017–2030)
Figure 29: Total incident cases of Soft tissue sarcoma (STS) in Japan (2017–2030)
Figure 30: Total incident cases of STS with lung metastases in Japan (2017–2030)
Figure 31: Gender-specific incident cases of STS with lung metastases in Japan (2017–2030)
Figure 32: Subtype-specific incident cases of STS with lung metastases in Japan (2017–2030)